FOXN3 controls liver glucose metabolism by regulating gluconeogenic substrate selection.


Journal

Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800

Informations de publication

Date de publication:
09 2019
Historique:
received: 30 07 2019
revised: 23 08 2019
accepted: 25 08 2019
entrez: 26 9 2019
pubmed: 26 9 2019
medline: 28 7 2020
Statut: ppublish

Résumé

The FOXN3 gene locus is associated with fasting blood glucose levels in non-diabetic human population genetic studies. The blood glucose-modifying variation within this gene regulates the abundance of both FOXN3 protein and transcript in primary human hepatocytes, with the hyperglycemia risk allele causing increases in both FOXN3 protein and transcript. Using transgenic and knock-out zebrafish models, we showed previously that FOXN3 is a transcriptional repressor that regulates fasting blood glucose by altering liver gene expression of MYC, a  master transcriptional regulator of glucose utilization, and by modulating pancreatic α cell mass and function through an unknown mechanism. Since homozygous Foxn3 null mice die perinatally, and heterozygous carries of the null allele are smaller than wild-type siblings, we examine the metabolic effects of decreasing mouse liver Foxn3 expression in adult life, performing dynamic endocrine tests not feasible in adult zebrafish. Fasting glucose, glucagon, and insulin; and dynamic responses to glucose, insulin, pyruvate, glutamine, and glucagon were measured. Gluconeogenic and amino acid catabolic gene expression was examined in livers, as well. Knocking down liver Foxn3 expression via transduction with adeno-associated virus serotype 8 particles encoding a short hairpin RNA targeting Fonx3 decreases fasting glucose and increases Myc expression, without altering fasting glucagon or fasting insulin. Liver Foxn3 knock-down confers increases glucose tolerance, has no effect on insulin tolerance or response to glucagon challenge, blunts pyruvate and glutamine tolerance, and modulates expression of amino acid transporters and catabolic enzymes. We conclude that liver Foxn3 regulates substrate selection for gluconeogenesis.

Identifiants

pubmed: 31552709
doi: 10.14814/phy2.14238
pmc: PMC6759504
doi:

Substances chimiques

Amino Acids 0
Blood Glucose 0
Cell Cycle Proteins 0
Forkhead Transcription Factors 0
Foxn3 protein, mouse 0
Insulin 0
RNA, Messenger 0
Glucagon 9007-92-5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14238

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK108833
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115824
Pays : United States
Organisme : NIDDK NIH HHS
ID : R56DK111494-01A1
Pays : United States
Organisme : NIDDK NIH HHS
ID : R56 DK111494
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020579
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK112826
Pays : United States
Organisme : NIH HHS
ID : P30DK020579
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK091317
Pays : United States

Informations de copyright

© 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.

Références

Diabetes. 2012 Jan;61(1):74-84
pubmed: 22187375
Mol Cell. 2019 Sep 5;75(5):967-981.e9
pubmed: 31300274
Cell Metab. 2015 Oct 6;22(4):682-94
pubmed: 26344101
Cell Rep. 2016 Jun 21;15(12):2745-55
pubmed: 27292639
Nat Med. 2018 May;24(4):518-524
pubmed: 29578539
BMJ Open Diabetes Res Care. 2019 Aug 30;7(1):e000688
pubmed: 31543974
Dev Dyn. 2007 Jan;236(1):226-39
pubmed: 17089409
Cell Metab. 2015 Oct 6;22(4):669-81
pubmed: 26344103
Genes Cancer. 2010 Jun;1(6):587-96
pubmed: 21113411
Nature. 2006 May 25;441(7092):537-41
pubmed: 16724069
Nature. 2018 Sep;561(7721):127-131
pubmed: 30150773
Annu Rev Nutr. 2017 Aug 21;37:51-76
pubmed: 28826372
PLoS Biol. 2015 Apr 22;13(4):e1002128
pubmed: 25901488
Nat Genet. 2012 May 13;44(6):659-69
pubmed: 22581228
Cell Rep. 2018 Jul 10;24(2):312-319
pubmed: 29996093
Physiol Rep. 2019 Sep;7(18):e14238
pubmed: 31552709
Biochem Biophys Res Commun. 2010 Sep 10;400(1):60-5
pubmed: 20691664
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12349-54
pubmed: 23836653
Mol Cell. 2019 Apr 18;74(2):245-253.e6
pubmed: 30826165
Diabetes. 2013 Apr;62(4):1196-205
pubmed: 23160527
Cell Metab. 2017 Jun 6;25(6):1348-1361.e8
pubmed: 28591637
Cell Rep. 2015 Jul 21;12(3):495-510
pubmed: 26166562
Cell Metab. 2017 Jun 6;25(6):1362-1373.e5
pubmed: 28591638
Front Oncol. 2019 May 31;9:234
pubmed: 31214487

Auteurs

Santhosh Karanth (S)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.
University of Utah Diabetes and Metabolism Research Center, Salt Lake City, Utah.
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, Utah.

Bhagirath Chaurasia (B)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.
University of Utah Diabetes and Metabolism Research Center, Salt Lake City, Utah.
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, Utah.

Faith M Bowman (FM)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.
University of Utah Diabetes and Metabolism Research Center, Salt Lake City, Utah.
Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah.

Trevor S Tippetts (TS)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.
University of Utah Diabetes and Metabolism Research Center, Salt Lake City, Utah.
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, Utah.

William L Holland (WL)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.
University of Utah Diabetes and Metabolism Research Center, Salt Lake City, Utah.
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, Utah.
Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah.

Scott A Summers (SA)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.
University of Utah Diabetes and Metabolism Research Center, Salt Lake City, Utah.
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, Utah.
Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah.

Amnon Schlegel (A)

University of Utah Molecular Medicine Program, Salt Lake City, Utah.
University of Utah Diabetes and Metabolism Research Center, Salt Lake City, Utah.
Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, Utah.
Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, Utah.
Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH